Standard BioTools Inc. (LAB)
| Market Cap | 360.93M |
| Revenue (ttm) | 85.33M |
| Net Income (ttm) | -74.90M |
| Shares Out | 390.07M |
| EPS (ttm) | -0.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,577,081 |
| Open | 0.894 |
| Previous Close | 0.899 |
| Day's Range | 0.886 - 0.940 |
| 52-Week Range | 0.870 - 1.720 |
| Beta | 1.42 |
| Analysts | Hold |
| Price Target | 1.35 (+45.9%) |
| Earnings Date | May 5, 2026 |
About LAB
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneo... [Read more]
Financial Performance
In 2025, Standard BioTools's revenue was $85.33 million, a decrease of -6.24% compared to the previous year's $91.01 million. Losses were -$74.90 million, -59.49% less than in 2024.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for LAB stock is "Hold" and the 12-month stock price target is $1.35.
News
Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results
BOSTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter and fiscal year ended Dec...
Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
BOSTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth quarter and full year 2025 financial results on Tuesday, February 24, ...
Standard BioTools Completes Sale of SomaLogic to Illumina
Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter a...
Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry
LOS ANGELES & SAN FRANCISCO--(BUSINESS WIRE)-- #Biotech--MI & Standard BioTools integrate HCR™ Gold with the Hyperion™ Imaging System to enable amplified RNA and protein detection for Imaging Mass Cyt...
Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks
Following global commercial launch in September, Illumina Protein Prep's "out of the box" solution drives extraordinary accessibility to proteomics for researchers, with over 40,000 samples processed ...
Standard BioTools Reports Third Quarter 2025 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended Septe...
Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish third quarter 2025 financial results on Tuesday, November 4, 20...
Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development
Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of disease Following early access program, custome...
Standard BioTools Reports Second Quarter 2025 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the second quarter ende...
Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study
PRECISE-SG100K will run 100,000 samples as part of an effort to transform precision health and medicine Reinforces SomaScan's strategic position in the high-impact biobank segment and its increasing r...
Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025
SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025...
Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy
Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumin...
Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina
Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single S...
Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series
Featuring top researchers and industry experts using high-throughput proteomics to drive breakthroughs in population health, translational research and clinical development Featuring top researchers a...
Standard BioTools Earnings Call Transcript: Q1 2025
Q1 2025 revenue was $40.8M, down 10% year-over-year, with strong instrument growth offset by softer consumables and services. Cost reductions and operational improvements drove better margins and lower losses, while full-year guidance remains unchanged amid ongoing macro headwinds.
Standard BioTools Reports First Quarter 2025 Financial Results
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the first quarter ended ...
Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025
Expanded suite of consumables, instruments and services designed to empower researchers and accelerate next-generation drug development Ninety posters and presentations at AACR powered by the Standard...
Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025
SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, a...
Standard BioTools Transcript: KeyBanc Annual Health Care Forum 2025
Disciplined M&A and operational efficiency have driven margin improvements and set the stage for profitability by 2026. SomaScan leads in plasma proteomics, supported by a strategic Illumina partnership and a focus on recurring consumable revenue. Academic exposure is limited, and the company is well-positioned for further consolidation.
Standard BioTools Transcript: TD Cowen 45th Annual Healthcare Conference
The company has rapidly built a strong proteomics-focused portfolio, achieving significant cost reductions and operational improvements. Strategic partnerships and M&A drive growth, with a focus on high-margin consumables and large-scale collaborations. Academic headwinds persist, but pharma demand is rebounding.
Standard BioTools to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that company management will participate in the following investor conferences:
Standard BioTools Earnings Call Transcript: Q4 2024
Q4 and full year 2024 revenue declined 9% year-over-year, but cost synergies and operational improvements drove a 33% improvement in Adjusted EBITDA. Consumables showed double-digit growth, while instruments and services faced headwinds from CapEx constraints and academic spending reductions. Strategic M&A and the Illumina partnership position the company for future growth.
Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the fourth quarter and ...
Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday...